Opthea Insiders
| OPTDelisted Stock | USD 3.41 0.07 2.01% |
Opthea employs about 33 people. The company is managed by 23 executives with a total tenure of roughly 77 years, averaging almost 3.0 years of service per executive, having 1.43 employees per reported executive. Breaking down Opthea's management performance can provide insight into the firm performance.
Opthea |
Opthea Management Team Effectiveness
The company has Return on Asset of (0.7334) % which means that on every $100 spent on assets, it lost $0.7334. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (33.8308) %, meaning that it generated no profit with money invested by stockholders. Opthea's management efficiency ratios could be used to measure how well Opthea manages its routine affairs as well as how well it operates its assets and liabilities.Opthea owns a total of 153.91 Million outstanding shares. Roughly 96.32 pct. of Opthea outstanding shares are held by general public with 3.68 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Opthea Workforce Comparison
Opthea is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 32,524. Opthea adds roughly 33.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Opthea Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Opthea insiders, such as employees or executives, is commonly permitted as long as it does not rely on Opthea's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Opthea insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Harrold Jason M over three months ago Disposition of 7000 shares by Harrold Jason M of OPTHEA at 0.68 subject to Rule 16b-3 | ||
Harrold Jason M over three months ago Acquisition by Harrold Jason M of 15000 shares of OPTHEA at 0.68 subject to Rule 16b-3 | ||
Harrold Jason M over three months ago Disposition of 15000 shares by Harrold Jason M of OPTHEA at 8.05 subject to Rule 16b-3 | ||
Harrold Jason M over three months ago Disposition of 785 shares by Harrold Jason M of OPTHEA at 6.37 subject to Rule 16b-3 | ||
Veru Dennison T over six months ago Discretionary transaction by Veru Dennison T of tradable shares of OPTHEA subject to Rule 16b-3 | ||
Harrold Jason M over six months ago Disposition of 25000 shares by Harrold Jason M of OPTHEA at 0.2 subject to Rule 16b-3 | ||
Bertrand Eric J over six months ago Disposition of tradable shares by Bertrand Eric J of OPTHEA subject to Rule 16b-3 | ||
Huber Richard L over six months ago Disposition of 50000 shares by Huber Richard L of OPTHEA at 0.45 subject to Rule 16b-3 |
Opthea Notable Stakeholders
An Opthea stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Opthea often face trade-offs trying to please all of them. Opthea's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Opthea's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Daniel MBA | Interim CFO | Profile | |
| Jen Watts | VP Operations | Profile | |
| Karen CPA | VP Secretary | Profile | |
| Dayong Li | Biometrics VP | Profile | |
| Kevin Bitter | VP Development | Profile | |
| CPA CPA | Chief Officer | Profile | |
| MD MA | Chief Advisor | Profile | |
| Sarika Gulhar | Executive Resources | Profile | |
| Michael Gerometta | Manufacturing Chemistry | Profile | |
| Peter MBA | Chief Officer | Profile | |
| Anand Sundaram | Vice Marketing | Profile | |
| PharmD MS | Chief Officer | Profile | |
| Kenneth Sall | Chief Officer | Profile | |
| Mike Campbell | Chief Officer | Profile | |
| Ian Leitch | Director Research | Profile | |
| James Goding | Independent Consultant | Profile | |
| MAICD MAICD | CEO MD | Profile | |
| MSc BPHARM | Senior Operations | Profile | |
| MD MBA | Chief Officer | Profile | |
| MS MD | Senior Development | Profile | |
| Annie Lee | F Mang | Profile | |
| Thomas Reilly | Chief Officer | Profile | |
| Fang Li | Senior Affairs | Profile |
About Opthea Management Performance
The success or failure of an entity such as Opthea often depends on how effective the management is. Opthea management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Opthea management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Opthea management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia. Opthea operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.
Please note, the imprecision that can be found in Opthea's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Opthea. Check Opthea's Beneish M Score to see the likelihood of Opthea's management manipulating its earnings.
Opthea Workforce Analysis
Traditionally, organizations such as Opthea use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Opthea within its industry.Opthea Manpower Efficiency
Return on Opthea Manpower
| Revenue Per Employee | 3.8K | |
| Revenue Per Executive | 5.4K | |
| Net Loss Per Employee | 6.7M | |
| Net Loss Per Executive | 9.6M | |
| Working Capital Per Employee | 3.8M | |
| Working Capital Per Executive | 5.4M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in Opthea Stock
If you are still planning to invest in Opthea check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Opthea's history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |